Newcourt Acquisition to Merge With Psyence Group's Clinical Trial Unit

NCAC

KYG6448C1033

Market Closed - Nasdaq Other stock markets 21:30:00 07/06/2024 BST			5-day change	1st Jan Change
0.67 ^USD	-3.80%		-10.67%	-92.75%

01-25	Newcourt Acquisition Corp(NasdaqGM:NCAC) dropped from NASDAQ Composite Index	CI
01-25	Psyence Therapeutics Corp. completed the acquisition of Newcourt Acquisition Corp from Newcourt SPAC Sponsor LLC, Polar Asset Management Partners Inc. and others in a reverse merger transaction.	CI

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about NEWT ACQU

Newcourt Acquisition Corp(NasdaqGM:NCAC) dropped from NASDAQ Composite Index	01-25	CI
Psyence Therapeutics Corp. completed the acquisition of Newcourt Acquisition Corp from Newcourt SPAC Sponsor LLC, Polar Asset Management Partners Inc. and others in a reverse merger transaction.	01-24	CI
Wall Street Set to Open Flat as Investors Eye Key Manufacturing Index	01-23	MT
Top Premarket Decliners	01-23	MT
Newcourt Acquisition Extends Closing Date for Merger; Shares Sink Premarket	01-23	MT
Newcourt Acquisition Extends Closing Date for Merger	01-23	MT
Top Premarket Decliners	01-18	MT
Newcourt Acquisition Corp announced that it expects to receive $10 million in funding from Psyence Therapeutics Corp.	01-14	CI
Newcourt Acquisition Corp Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-21	CI
Newcourt Acquisition Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Newcourt Acquisition Corp announced that it expects to receive $0.75 million in funding	12/07/23	CI
Newcourt Acquisition Corp. Appoints Jurgen Van De Vyver as Chief Financial Officer	16/06/23	CI
Newcourt Acquisition Corp Announces Resignation of Daniel Rogers as Daniel Rogers	12/06/23	CI
Newcourt Acquisition Corp Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Newcourt Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Newcourt Acquisition Corp Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Newcourt Acquisition Corp Auditor Raises 'Going Concern' Doubt	22/03/23	CI
Newcourt Acquisition Corp announced that it has received $0.495 million in funding	16/01/23	CI
Refile: Psyence Details Business Combination Between Subsidiary Psyence Biomed and Nasdaq-listed Newcourt Acquisition Corp	10/01/23	MT
Psyence Details Business Combination Between Subsidiary Psyence Biomed and Nasdaq-listed Newcourt Acquisition Corp	10/01/23	MT
Newcourt Acquisition to Merge With Psyence Group's Clinical Trial Unit	10/01/23	MT
Psyence Therapeutics Corp. entered into a definitive business combination agreement to acquire Newcourt Acquisition Corp from Newcourt SPAC Sponsor LLC, Polar Asset Management Partners Inc. and others for $50 million in a reverse merger transaction.	08/01/23	CI
Newcourt Acquisition Corp announced that it expects to receive $0.495 million in funding	05/01/23	CI
Newcourt Acquisition Corp Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
Newcourt Acquisition Corp Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	15/08/22	CI

Newcourt Acquisition Corp. is a blank check company. The Company was formed for the purpose of effecting a merger, capital exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company has not identified any specific business combination target and has not, nor has anyone on behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. The Company has not commenced any operations and has not commenced any revenues.

Sector

More about the company

Income Statement Evolution

More financial data

NEWT ACQU

Equities

NCAC

KYG6448C1033

Latest news about NEWT ACQU

Chart NEWT ACQU

Company Profile

Income Statement Evolution